Evidence map›Paper›PMID 27567830›Full record

ArticleJournal of Alzheimer's disease : JAD2016

Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid?

Philip S J Weston, Ross W Paterson, John Dickson, Anna Barnes, Jamshed B Bomanji, Irfan Kayani, Michael P Lunn, Catherine J Mummery, Jason D Warren, Martin N Rossor and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives.European journal of nuclear medicine and molecular imaging · 2021
    Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Brain Amyloid in Sporadic Young Onset Alzheimer's Disease.Journal of Alzheimer's disease reports · 2023
    Article
  6. Clinical impact of amyloid PET usingAnnals of nuclear medicine · 2022
    Article
  7. Article
  8. Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer's disease.European journal of nuclear medicine and molecular imaging · 2020
    Article
  9. Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?Journal of Alzheimer's disease : JAD · 2020
    Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Philip S J WestonDementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.
Ross W PatersonDementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.
John DicksonInstitute of Nuclear Medicine, University College London Hospitals, London, UK.
Anna BarnesInstitute of Nuclear Medicine, University College London Hospitals, London, UK.
Jamshed B BomanjiInstitute of Nuclear Medicine, University College London Hospitals, London, UK.
Irfan KayaniInstitute of Nuclear Medicine, University College London Hospitals, London, UK.
Michael P LunnDepartment of Molecular Neuroscience, UCL Institute of Neurology, University College London, UK.
Catherine J MummeryDementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.
Jason D WarrenDementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.
Martin N RossorDementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.
Nick C FoxDementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.
Henrik ZetterbergDepartment of Molecular Neuroscience, UCL Institute of Neurology, University College London, UK.
Jonathan M SchottDementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.
UK Dementia Research Institute · GBRoyal London Hospital · GBUniversity College London · GB

Funding

Medical Research Council MR/L023784/1Medical Research Council MR/L023784/2Medical Research Council MR/M003108/1
6 · The paper itself

Abstract

Cerebrospinal fluid (CSF) measures of amyloid and tau are the first-line Alzheimer's disease biomarkers in many clinical centers. We assessed if and when the addition of amyloid PET following CSF measurements provides added diagnostic value. Twenty patients from a cognitive clinic, who had undergone detailed assessment including CSF measures, went on to have amyloid PET. The treating neurologist's working diagnosis, and degree of diagnostic certainty, was assessed both before and after the PET. Amyloid PET changed the diagnosis in 7/20 cases. Amyloid PET can provide added diagnostic value, particularly in young-onset, atypical dementias, where CSF results are borderline and diagnostic uncertainty remains.

Indexed as

Positron-Emission TomographyAgedAmyloid beta-PeptidesBiomarkersDementiaFemaleHumansMaleMiddle AgedPeptide Fragmentstau ProteinsAmyloid beta-Peptidesamyloid beta-protein (1-42)BiomarkersMAPT protein, humanPeptide Fragmentstau ProteinsAlzheimer’s diseasebiomarkercerebrospinal fluidclinical decision-makingdiagnosisPET

Identifiers

PMID27567830
PMCPMC5181662
OpenAlexW2510151956

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.